Efficacy and safety of iruplinalkib (WX-0593) in ALK -positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)
文献类型：期刊论文
| 作者 | Yuankai Shi1; Jianhua Chen2; Helong Zhang3; Zhihong Zhang4; Yiping Zhang5; Zhehai Wang6; Shucai Zhang7; Jian Zhao8; Chunling Liu9; Xiuwen Wang10 |
| 刊名 | BMC MEDICINE
 |
| 卷号 | 21期号:1 |
| ISSN号 | 1741-7015 |
| 英文摘要 | Iruplinalkib (WX-0593) is an anaplastic lymphoma kinase (ALK) ALK -positive crizotinib-resistant advanced non-small cell lung cancer (NSCLC) patients. |
| 语种 | 英语 |
| 源URL | [http://ir.yic.ac.cn/handle/133337/34542]  |
| 专题 | 中国科学院烟台海岸带研究所 |
| 作者单位 | 1.中国医学科学院北京协和医学院 2.Hunan Tumor Hospital 3.the Second Affiliated Hospital of Air Force Medical University 4.Anhui Provincial Cancer Hospital 5.Zhejiang Cancer Hospital 6.Respiratory Medical Oncology Ward II, Shandong Provincial Institute of Cancer Prevention and Treatment 7.首都医科大学 8.广州医科大学 9.The Affiliated Tumour Hospital of Xingjiang Medical University 10.山东大学 |
| 推荐引用方式 GB/T 7714 | Yuankai Shi,Jianhua Chen,Helong Zhang,et al. Efficacy and safety of iruplinalkib (WX-0593) in ALK -positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)[J]. BMC MEDICINE,21(1). |
| APA | Yuankai Shi.,Jianhua Chen.,Helong Zhang.,Zhihong Zhang.,Yiping Zhang.,...&Xiaoyan Kang. |
| MLA | Yuankai Shi,et al."Efficacy and safety of iruplinalkib (WX-0593) in ALK -positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)".BMC MEDICINE 21.1 |
入库方式： OAI收割
来源：烟台海岸带研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。